EVATANE EVA法国阿科玛

典型特性

特性值单位试验方法

乙酸乙烯酯含量27-29%Wt FTIR（内标法）

熔融指数（190°C/2.16 kg）135-175 g/10分钟ISO 1133/ASTM D1238

密度（23°C）0.95 g/cm3 ISO 1183

熔点69°C ISO 11357-3

维卡软化点（10N）<40°C ISO 306/ASTM D1525

环和球温度95°C ASTM E28/NF EN 1238

断裂伸长率400-600%ISO 527/ASTM D638

断裂抗拉强度8mpa ISO 527/ASTM D638

肖氏硬度A 71-ISO 868/ASTM D2240

应用

EVATAN®23-150的高醋酸乙烯酯含量带来柔软性、柔韧性和极性。

EVATANE®28-150与大多数增粘树脂和蜡相容。加上高流动性，

它是一种高效、易操作的热熔胶配方产品。它也可以用作

原油添加剂（降凝剂）。

有关您的具体申请的详细信息和建议，请联系

你当地的阿科马技术代表。

处理

EVATANE®28-150可以在热塑性塑料的大多数传统设备上加工。它是

建议避免熔体温度超过230°C，并在运行后清洗设备

完整的。

ARKEMA Anonymous公司，资本欧元-RCS Nanterre

很好，操作和安全

EVATANE 28-150应储存在标准条件下，并防止紫外线照射。不合适的

储存条件可能导致降解，并可能对

产品。

提供安全数据表以及有关处理和储存依凡烷28-150的信息

如有要求，请联系您的ARKEMA代表或访问网站evatane.com。

保质期

自交货之日起两年，未开封包装。任何超过此限值的用途，请参阅

我们的技术服务。

EVATANE EVA法国阿科玛

良好的柔韧性 ;流动性高 ;柔软 ;无规共聚物

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods

of use of the product and of the information referred to herein are beyond our control, ARKEMA expressly disclaims any and all liability as to any results obtained

or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF

MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED

HEREIN.

The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other

materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice

under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any

proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations. Arkema has implemented a Medical Policy regarding

the use of Arkema products in Medical Devices applications that are in contact with the body or circulating bodily fluids:

Arkema has designated Medical grades to be used for such Medical Device applications. Products that have not been designated as Medical grades are not authorized

by Arkema for use in Medical Device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any

Arkema products in Medical Device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema

trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable

devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components,

including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with

all applicable legal and regulatory re (FDA or other national drug agencies) It is the sole responsibility of the manufacturer of the medical device to conduct all

necessary tests and inspections and to evaluate the medical device under actual end-use re and to ade advise and warn purchasers, users, and/or learned

intermediaries (such as physicians) of pertinent risks and fulfill any post market surveillance obligations. Any decision regarding the appropriateness of a particular Arkema

material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

Any claim relating to defects or non-compliance of the products shall be valid only if it is sent to Arkema in writing within fifteen (15) calendar days following delivery

of the Product.